New developments in the treatment of attention-deficit/hyperactivity disorder

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 8, 2006, Pages 3-6

  Biederman, Joseph ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WAC 725 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CLONIDINE; DESIPRAMINE; GUANFACINE; METHYLPHENIDATE; MODAFINIL; PEMOLINE;

ATTENTION DEFICIT DISORDER; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG COATING; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; GENETIC ASSOCIATION; HUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; TABLET FORMULATION;

EID: 33748676080     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000;105:1158-1170
2. Wilens TE, Biederman J, Spencer TJ, et al. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. J Clin Psychopharmacol 1995;15:270-278
3. Himpel S, Banaschewski T, Heise CA, et al. The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder. Expert Opin Drug Saf 2005;4:311-321
4. Amsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci 1988;8:4287-4298
5. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2001;21:223-228
6. Muller U, Clark L, Lam ML, et al. Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. Psychopharmacology (Berl) 2005;182:205-213
7. Posey DJ, Puntney JI, Sasher TM, et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004;14:233-241
8. Scahill L, Chappell PB, Kim YS, et ai. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158:1067-1074
9. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995;34:1140-1146
10. Waxmonsky JG. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults. Essent Psychopharmacol 2005;6:262-276
11. Pelham WE, Burrows-Maclean L, Gnagy EM, et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol 2005;13:111-126
12. Pelham WE Jr, Manos MH, Ezzell CE, et al. A dose-ranging study of methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005;44:522-529
13. Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 2006;67:137-147
14. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005;116:777-784